Title	Publication Date	Language	Citations
Nomograms in oncology: more than meets the eye	2015/04/01	English	176
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial	2009/01/01	English	107
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial	2009/05/01	English	107
Definition and classification of cancer cachexia: an international consensus	2011/05/01	English	99
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China	2020/03/01	English	97
Cancer-related inflammation and treatment effectiveness	2014/10/01	English	96
A review of human carcinogens—Part B: biological agents	2009/04/01	English	80
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial	2012/03/01	English	76
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study	2017/09/01	English	73
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial	2018/07/01	English	71
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma	2014/11/01	English	69
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study	2011/08/01	English	63
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial	2018/11/01	English	59
Predictive biomarkers for checkpoint inhibitor-based immunotherapy	2016/12/01	English	59
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study	2020/10/01	English	58
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study	2019/09/01	English	56
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis	2012/06/01	English	51
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial	2010/02/01	English	49
Breast cancer in China	2014/06/01	English	49
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics	2017/03/01	English	48
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial	2014/10/01	English	48
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial	2015/04/01	English	47
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study	2017/03/01	English	47
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial	2014/02/01	English	46
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy	2018/01/01	English	44
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial	2020/01/01	English	44
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial	2017/03/01	English	44
Global cancer transitions according to the Human Development Index (2008–2030): a population-based study	2012/08/01	English	44
Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study	2008/07/01	English	43
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial	2019/02/01	English	41